KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Hoimes, CJ; Graff, JN; Tagawa, ST; Hwang, C; Kilari, D; Ten Tije, AJ; Omlin, A; McDermott, RS; Vaishampayan, UN; Elliott, T; Gerritsen, WR; Wu, H; Kim, J; Schloss, C; De Bono, JS; Antonarakis, ES

Published Date

  • May 20, 2020

Published In

Volume / Issue

  • 38 / 15

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X